Lung Vision System

by Body Vision Medical  · Based in Israel → — Transforming Lung Cancer Intervention with Real-Time AI Imaging
Cardiothoracic Surgery Interventional Radiology Pulmonology

Affordable
Regulatory Status Disclosed

Overview

The LungVision® System by Body Vision Medical is an AI-powered, intraoperative imaging and navigation system designed to revolutionize lung cancer diagnostics and interventions. It transforms images from any conventional 2D C-arm into real-time 3D images, providing pulmonologists and thoracic surgeons with enhanced visualization and guidance during bronchoscopy procedures.

Utilizing proprietary AI Tomo® technology, LungVision corrects for CT-to-body divergence, a common challenge in traditional navigation systems, and offers visual tool-in-lesion confirmation. This enables clinicians to accurately locate and biopsy even small, peripheral lung lesions with greater precision, confidence, and simplicity.

The system is hardware-light, offering an affordable, low-cost solution with a small, mobile footprint, and seamlessly integrates with existing 2D and 3D C-arms, navigation platforms, bronchoscopes (including robotic), and biopsy tools. LungVision has demonstrated improved diagnostic yields, approaching 90-95%, and significantly reduces radiation exposure compared to 3D C-arms.

It supports comprehensive workflow from planning (including virtual bronchoscopy) to real-time navigation and lesion localization, aiming to facilitate earlier diagnosis and more effective treatment of lung cancer.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered 3D imaging from 2D C-arms
  • Real-time intraoperative navigation and lesion localization
  • Correction for CT-to-body divergence
  • Augmented fluoroscopy with tool-in-lesion confirmation
  • Compatibility with existing bronchoscopes, C-arms, and biopsy tools (including robotic)
  • Reduced radiation exposure (up to 1/5 of 3D C-arms)
  • Affordable, hardware-light, mobile footprint
  • Improved diagnostic yield (approaching 90-95%)
  • Virtual bronchoscopy for pathway planning
  • C-Arm Based Tomography (CABT)

Use Cases

  • Peripheral pulmonary nodule biopsy
  • Early lung cancer diagnosis
  • Image-guided navigation during bronchoscopy procedures
  • Delivery of localized therapies
  • Diagnosis and treatment in a single-anesthesia event
  • Accessing smaller, hard-to-visualize, and more peripheral lesions

What Physicians Need to Know

Key Capabilities
The LungVision System uses AI to transform X-ray images from any C-arm into real-time, intraoperative CT scans, providing 3D imaging that rivals cone-beam CT quality. It offers real-time navigation and enhanced visualization, enabling bronchoscopists to biopsy from smaller, more difficult-to-access lung lesions. The system also provides augmented fluoroscopy with an overlay of the actual lesion location and an interactive 3D view. It supports virtual bronchoscopy for pathway planning and offers AI Tomography imaging with a larger field of view. The system also features improved reach and fidelity of virtual bronchoscopy in peripheral airways and an improved pathway planning experience. It can be used as a standalone platform or as an adjunct to robotic bronchoscopy platforms.
Clinical Utility
LungVision empowers bronchoscopists to biopsy smaller, harder-to-reach lung lesions at an earlier stage, maximizing the likelihood of early lung cancer diagnosis and improving survival rates. It enables accurate real-time navigation and lesion localization during bronchoscopic procedures, providing visual confirmation of tool-in-lesion and correcting for CT-to-body divergence. The system facilitates the diagnosis and treatment of suspicious pulmonary lesions in a single anesthesia event. It has been shown to improve diagnostic yield, with one study reporting an 88.2% diagnostic accuracy at 12 months follow-up and another showing an improvement from 74% to 88% in diagnostic yield. The system aims to provide similar diagnostic success rates as transthoracic needle aspiration (TTNA) but with a less invasive approach.
Integration Options
The LungVision System is designed for seamless integration with existing equipment, including 2D and 3D C-arms, navigation platforms, bronchoscopes (including robotic), and biopsy tools. It can enhance robotic bronchoscopy platforms like Ethicon MONARCH™ and Intuitive's Ion by providing real-time intraoperative imaging.
Compliance Status
The LungVision System received FDA clearance in May 2017. It has also received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in India and in Australia. The system has EU-MDR Certification.
Pricing Model
Body Vision Medical offers a subscription model for LungVision, allowing hospitals to acquire the system without significant capital expenditure. The system is designed to be affordable and cost-effective, minimizing capital costs and offering optional disposables to manage per-procedure costs. It is presented as a fraction of the cost of electromagnetic navigation (EMN), robotics, or cone-beam CT (CBCT).
User Experience
The system is designed to be easy-to-use, empowering users with real-time, intraoperative imaging for accurate lesion localization and biopsy with greater precision, confidence, and simplicity. It aims to streamline procedural workflow for healthcare providers. The latest software update (v2.27) introduces impactful user experience improvements, particularly during peripheral scope navigation.
Support Quality
Body Vision Medical offers extended warranty service plans for reliable, certified, and expedited support. They also provide advanced clinical training and case support to ensure user confidence and success.
Implementation Complexity
The LungVision System is designed for seamless integration into existing procedural workflows and leverages existing hospital equipment, reducing implementation costs. Its hardware-light design offers a small, mobile footprint. The system's compatibility with standard equipment in the bronchoscopy suite helps lower costs and offers navigation capabilities even in medical centers with financial limitations.
Evidence Base
Clinical case studies and publications are available on the Body Vision Medical website. Studies have assessed the diagnostic yield and safety of the LungVision system, with one reporting an average distance of 5.9 mm between augmented fluoroscopy and actual lesion location, and an 88.2% diagnostic accuracy at 12 months follow-up. Another study at Cleveland Clinic showed an improvement in diagnostic yield by 14.5% (from 74% to 88%) and estimated savings of $2,700 per case when using LungVision standalone compared to robotic bronchoscopy. The system has been the subject of numerous presentations and videos at medical conferences.
Physician Tip

The LungVision System offers real-time, intraoperative 3D imaging, which can significantly enhance the precision and confidence in biopsying small, peripheral lung lesions. Its compatibility with existing C-arms and bronchoscopy equipment, including robotic platforms, allows for flexible integration into current workflows. Physicians can leverage its AI-powered navigation to overcome challenges like CT-to-body divergence and improve diagnostic yield. The ability to perform diagnosis and treatment in a single anesthesia event can also be beneficial for patient care.

The LungVision System is designed to integrate seamlessly with various existing equipment in the bronchoscopy suite. This includes 2D and 3D C-arms, different navigation platforms, and a wide range of bronchoscopes (both traditional and robotic) and biopsy tools. This broad compatibility allows healthcare facilities to utilize their current infrastructure, potentially reducing the need for extensive new equipment purchases.

Details

Category Oncology AI, Radiology & Imaging AI, Surgical AI
Pricing Affordable
DeploymentOn-premise (hardware-light design, mobile footprint)
Mobile AppThe system includes an innovative tablet for total control of the LungVision™ system from any location in the room.
TrainingUnknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Cardiothoracic Surgery, Interventional Radiology, Pulmonology

Support & Reliability

Training ProvidedUnknown

What the Web Says

The Body Vision Medical Lung Vision System is an AI-driven, intraoperative imaging platform designed to improve the diagnosis of peripheral lung nodules. It utilizes augmented fluoroscopy and AI Tomo® technology to provide 3D imaging that rivals cone-beam CT quality while minimizing radiation dose and cost. The system aims to enhance the diagnostic yield and safety of bronchoscopic procedures, making it a valuable tool for early detection and characterization of lung nodules.

Overall: Positive

Strengths

  • Improved diagnostic yield compared to traditional methods.
  • Minimizes radiation dose and cost compared to cone-beam CT.
  • Provides real-time, intraoperative 3D imaging for precise navigation and biopsy.
  • Compatible with standard bronchoscopy equipment and biopsy tools, including cryoprobes.
  • Enhances confidence in biopsying smaller, peripheral nodules.
  • Easy to use, fast, and provides clear, interpretable results for clinicians.

Limitations

  • Some studies have noted a short follow-up period for patients.
  • Randomized controlled trials are still needed to definitively ascertain its diagnostic yield.
  • Bleeding complications were reported in some procedures, though mostly mild to moderate.

Based on reviews from: fda.gov, nih.gov, bmj.com, bodyvisionmedical.com, medicaltechoutlook.com, prnewswire.com, auntminnie.com, ijircce.com, innolitics.com

Last updated: 2026-10-29

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Lung Vision System

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

MDPI
Initial Experience of Ultrathin Cryobiopsy Combined with Lung Vision Platform for Pulmonary Nodules
A study published in October 2024 evaluated the effectiveness and safety of integrating an ultrathin cryoprobe with the Lung Vision system for diagnosing pulmonary nodules. The research concluded that this combined approach offers a favorable safety profile and significant diagnostic yield for early detection and characterization of lung nodules.
2024-10
Beyond Air
Beyond Air Appoints David Webster as Chief Commercial Officer
In June 2024, Beyond Air announced the appointment of David Webster as their Chief Commercial Officer. Webster previously served as CEO of Body Vision Medical, where he led the global commercialization of the Lung Vision system.
2024-06
StockTitan
Beyond Air Appoints David Webster as Chief Commercial Officer
David Webster, former CEO of Body Vision Medical, who was responsible for the global commercialization of the Lung Vision system, was appointed Chief Commercial Officer at Beyond Air in June 2024.
2024-06
Nasdaq
Beyond Air Appoints David Webster as Chief Commercial Officer
David Webster, who previously served as CEO of Body Vision Medical and oversaw the global commercialization of the Lung Vision system, was appointed Chief Commercial Officer of Beyond Air in June 2024.
2024-06
Investing.com
Beyond Air Appoints David Webster as Chief Commercial Officer
In June 2024, Beyond Air announced the appointment of David Webster as Chief Commercial Officer. Webster's prior role was CEO of Body Vision Medical, where he led the global commercialization of the Lung Vision system.
2024-06
FDA
Lung Vision System
The Lung Vision System received 510(k) clearance from the FDA on April 18, 2019. The applicant was Bodyvision Medical, Ltd.
2019-04
Innolitics
Lung Vision System 510(k) Summary
The Lung Vision System is designed to assist catheter/device navigation during pulmonary procedures by segmenting 3D CT datasets and overlaying them with live X-ray images. It received FDA 510(k) clearance on April 18, 2019.
2019-04
medecine.ai
Lung Vision System, dispositif d'IA médicale de Body Vision Medical Ltd.
The Lung Vision System, an AI-powered medical device by Body Vision Medical Ltd. for Radiology, was authorized by the FDA on April 18, 2019, via the 510(k) pathway (K183593).
2019-04

Videos

Product demos, reviews, and walkthroughs for Lung Vision System.

View all on YouTube

Frequently Asked Questions

The LungVision System uses AI to transform X-ray images from any C-arm into real-time, intraoperative CT scans. This AI-powered imaging enables bronchoscopists to visualize the actual pulmonary lesion and its location during a diagnostic bronchoscopy procedure, guiding biopsy from smaller, harder-to-access lung lesions at an earlier stage.
The LungVision System offers several advantages, including real-time, intraoperative 3D imaging that rivals cone-beam CT quality with reduced radiation dose. It corrects for CT-to-body divergence, which is the difference between a lesion's preoperative CT location and its actual location during bronchoscopy, increasing diagnostic confidence and yield. It also integrates with existing equipment, including any C-arm and robotic bronchoscopy platforms, making it a cost-effective solution.
The LungVision System includes hardware and complies with ANSI/AAMI/ES 60601-1:2005(2012) and IEC 60601-1-2:2014 standards. It has received regulatory approvals in various countries, including India, Singapore, Brazil, and Australia.
While the LungVision system significantly improves diagnostic yield, early reports indicate that more data is needed to fully assess its diagnostic yield and safety, particularly when combined with transbronchial cryobiopsy. Historically, diagnostic bronchoscopy has had a lower success rate compared to TTNA, and while LungVision aims to address this, it's important to consider the ongoing research and data collection.
The LungVision System is designed for seamless integration with existing equipment. It transforms X-ray images from any conventional C-arm into real-time 3D images and can be used as a standalone navigation and imaging system or as an adjunct to augment robotic bronchoscopy platforms. It also integrates with standard biopsy instruments, including the cryoprobe.
Alternatives to the LungVision System include electromagnetic navigation bronchoscopy (ENB), robotic bronchoscopy platforms, and cone-beam CT (CBCT) systems. However, these alternatives may have limitations such as reliance on virtual navigation from pre-operative CT scans, higher costs, or greater radiation exposure compared to LungVision's AI-powered approach.
Studies have shown diagnostic yields approaching 90% and beyond with the LungVision System. One study reported an overall diagnostic yield of 77.8%, with 81.8% for the second-generation system, and 72.2% for nodules smaller than 20 mm. The system's ability to correct for CT-to-body divergence and provide visual tool-in-lesion confirmation contributes to this improved accuracy.

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

More from Body Vision Medical

Lung Vision
Body Vision Medical
Oncology AI
LungVision by Body Vision Medical is an AI-powered, intraoperative imaging system that converts 2D C-arm images into real-time 3D views for precise navigation and visual confirmation during lung biopsies, enhancing early lung cancer detection and treatment.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.